STOCK TITAN
  1. Home
  2. News
  3. BMRN

BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

SAN RAFAEL, Calif., July 14, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, July 28, at 4:30 p.m. ET to discuss second quarter 2021 financial results and provide a general business update.

Dial-in Number 
U.S. / Canada Dial-in Number: (866) 502-9859
International Dial-in Number: (574) 990-1362
Conference ID: 8363378

Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 8363378

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:

Investors 

Media

Traci McCarty 

Debra Charlesworth

BioMarin Pharmaceutical Inc. 

 BioMarin Pharmaceutical Inc.

(415) 455-7558 

(415) 455-7451

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-second-quarter-2021-financial-results-conference-call-and-webcast-on-wednesday-july-28-at-430pm-et-301333393.html

SOURCE BioMarin Pharmaceutical Inc.

Stock BMRN logo
BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

BMRN Rankings

#640 Ranked by Market Cap
#2446 Ranked by Stock Gains
N/A Ranked by Dividends

BMRN Latest News

May 8, 2024
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
May 4, 2024
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
Apr 24, 2024
BioMarin Reports Record Financial Results for the First Quarter 2024
Apr 10, 2024
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
Mar 12, 2024
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

BMRN Stock Data

14.63B
187.23M
0.84%
100.76%
1.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NOVATO

About BMRN

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment